LogoThe Incretin Space
Login
Subscribe
LogoThe Incretin Space
Gallery

The Incretin Space

A collection of collated data on incretin drug developments, including new drugs, new treatments and the future of incretins in medicine

Written by

The Incretin Space

Most Recent

Surv-ing up Diabetes

Oct 12, 2026

Surv-ing up Diabetes

Survodutide syncs a type 2 diabetes win with caveats

Read more
arrow-right
Clearing the CVOT hurdle

Oct 7, 2026

Clearing the CVOT hurdle

Not ‘kidneying’ around about orforglipron’s potential benefits

Read more
arrow-right
EASD 2026: The weight equation is solved?

Oct 5, 2026

EASD 2026: The weight equation is solved?

Retatrutide and EloraTirz provide shock and awe at EASD

Read more
arrow-right
Advancing Insulin Sensitivity Training

Sep 29, 2026

Advancing Insulin Sensitivity Training

Or how tirzepatide became king and GIP is why

Read more
arrow-right
Brenipatide, VK2735 and Enicepatide

Sep 24, 2026

Brenipatide, VK2735 and Enicepatide

All hail the current and future GIP kings

Read more
arrow-right
(Insulin) Sensitivity Training

Sep 14, 2026

(Insulin) Sensitivity Training

An intro guide to a misunderstood metric of diabetic and cardiometabolic risk

Read more
arrow-right
The Clue is in Ketones

Aug 31, 2026

The Clue is in Ketones

Retatrutide's metabolomics data reveals hints about weight loss differences between diabetics and non-diabetics

Read more
arrow-right
Retatrutide revolution continues

Jul 28, 2026

Retatrutide revolution continues

Weight loss remains the star of the show, but cardiovascular data was underpowered

Read more
arrow-right
Read all
arrow-right

Archive

Surv-ing up Diabetes

Oct 12, 2026

•

5 min read

Surv-ing up Diabetes

Survodutide syncs a type 2 diabetes win with caveats

David W
David W

Tirzepatide

+1

Clearing the CVOT hurdle

Oct 7, 2026

•

6 min read

Clearing the CVOT hurdle

Not ‘kidneying’ around about orforglipron’s potential benefits

David W
David W

GLP-1

+5

EASD 2026: The weight equation is solved?

Oct 5, 2026

•

16 min read

EASD 2026: The weight equation is solved?

Retatrutide and EloraTirz provide shock and awe at EASD

David W
David W

Tirzepatide

+1

Advancing Insulin Sensitivity Training

Sep 29, 2026

•

10 min read

Advancing Insulin Sensitivity Training

Or how tirzepatide became king and GIP is why

David W
David W
Brenipatide, VK2735 and Enicepatide

Sep 24, 2026

•

11 min read

Brenipatide, VK2735 and Enicepatide

All hail the current and future GIP kings

David W
David W

GLP-1

+2

(Insulin) Sensitivity Training

Sep 14, 2026

•

15 min read

(Insulin) Sensitivity Training

An intro guide to a misunderstood metric of diabetic and cardiometabolic risk

David W
David W

Glucagon

+2

The Clue is in Ketones

Aug 31, 2026

•

10 min read

The Clue is in Ketones

Retatrutide's metabolomics data reveals hints about weight loss differences between diabetics and non-diabetics

David W
David W

GLP-1

+3

Retatrutide revolution continues

Jul 28, 2026

•

7 min read

Retatrutide revolution continues

Weight loss remains the star of the show, but cardiovascular data was underpowered

David W
David W

GLP-1

+1

What is the deal with liver concerns in small molecule GLP-1s?

Jul 16, 2026

•

10 min read

What is the deal with liver concerns in small molecule GLP-1s?

A guest post by Jen Can NuSH on liver concerns and small molecule GLP1 medications

David W
JenCanNuSH
David W, +1
The Incretin Space

The Incretin Space

A collection of collated data on incretin drug developments, including new drugs, new treatments and the future of incretin in medicine


Home

Posts

© 2026 The Incretin Space.
beehiivPowered by beehiiv